GO
Loading...

Mergers and Acquisitions

More

  • Can Modi lure foreign businesses to India? Wednesday, 23 Apr 2014 | 7:11 PM ET
    Flower petals are thrown around Bharatiya Janata Party (BJP) leader Narendra Modi as he rides in an open jeep on his way to file nomination papers on April 9, 2014 in Vadodra, India.

    Global business leaders eyeing expansion into India will be closely watching the outcome of the country’s general elections due to conclude on May 16.

  • Carl Icahn to seed activist funds     Wednesday, 23 Apr 2014 | 10:33 AM ET

    CNBC's David Faber asks investor Carl Icahn if he succeeded in his eBay and Apple campaigns. Icahn also discuss his plans to seed other activist funds.

  • I did not front-run Allergan stock, Ackman says Wednesday, 23 Apr 2014 | 9:40 AM ET
    Bill Ackman

    Bill Ackman also tells CNBC that Allergan's poison-pill defense doesn't make his takeover bid more difficult.

  • William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.

  • Ackman: Allergan clear fit for Valeant     Wednesday, 23 Apr 2014 | 7:41 AM ET

    William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.

  • J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.

  • Valeant CEO: Allergan has a great set of assets     Wednesday, 23 Apr 2014 | 7:33 AM ET

    J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.

  • Ackman: Valeant fit into Pershing investing mold     Wednesday, 23 Apr 2014 | 7:32 AM ET

    William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.

  • Investor pressure pushing drugmaker M&A deals Wednesday, 23 Apr 2014 | 6:11 AM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.

  • Comcast nears subscriber deal with Charter Wednesday, 23 Apr 2014 | 1:32 AM ET
    A Comcast truck in Pompano Beach, Florida

    Comcast may divest about 4 million subscribers after its merger with Time Warner Cable and may sell a portion to Charter Communications.

  • China Huiyuan: We can learn from Suntory     Tuesday, 22 Apr 2014 | 7:24 PM ET

    Zhu Xinli, Chairman of China Huiyuan Juice Group, the country's biggest juice maker, says it can learn from Suntory's technology to provide high-quality tea.

  • Discussing new technology in the Permian, growing market in North America, and higher earnings, with Dave Lesar, Halliburton chairman, president and CEO.

  • Fast Money Final Trade: C, CTRL, URI, FB     Tuesday, 22 Apr 2014 | 5:58 PM ET

    The Fast Money traders share their final trades of the day.

  • Stock Pops & Drops: KORS, LXK, PHG, CONN     Tuesday, 22 Apr 2014 | 5:45 PM ET

    The Fast Money traders take a look at today's biggest market movers.

  • Activist Jana sees opportunities in this stock Tuesday, 22 Apr 2014 | 4:07 PM ET
    Barry Rosenstein, founder and managing partner of Jana Partners

    Walgreen's pending acquisition of Alliance Boots can mean lower taxes and a better company, according to activist investor Barry Rosenstein.

  • Botox. It's more than just a wrinkle buster Tuesday, 22 Apr 2014 | 2:18 PM ET
    Botox by Allergan

    More than half the revenue from Botox comes from therapeutic, not cosmetic, use. And its potential is helping to make Allergan an attractive target.

  • Valeant and Allergan a 'perfect match': Shareholder Tuesday, 22 Apr 2014 | 11:32 AM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    One of Valeant's top shareholders on Tuesday threw his support behind its proposed takeover bid for Botox-maker Allergan.

  • CNBC's David Faber and Jeffrey Ubben, ValueAct Capital Partners CEO, discuss the job performance of Microsoft CEO Satya Nadella and the likelihood of the Nokia deal closing.

  • Allergan, Valeant perfect match: CEO     Tuesday, 22 Apr 2014 | 10:48 AM ET

    CNBC's David Faber and Jeffrey Ubben, ValueAct Capital Partners CEO, discuss Valeant Pharmaceuticals bid for Allergan and why Valeant needed investor Bill Ackman involved in the deal.

  • Novartis strikes multiple deals     Tuesday, 22 Apr 2014 | 9:09 AM ET

    The "Squawk on the Street" news team discuss all the M&A activity going on in pharma after Novartis is reported to be purchasing GlaxoSmithKline's oncology products unit for $14.5 billion. Separately Novartis is selling its animal health division to Eli Lilly for $5.4 billion in cash.

Contact Mergers & Acquisitions

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Private Equity

Most Popular Video

Wednesday, 23 Apr 2014 | 4:32 PM ET

Apple is reporting Q2 EPS of $11.62 on revenue of $45.6 billion. Gene Munster, Piper Jaffray senior research analyst, says investors should feel a sense of relief on these numbers.

Wednesday, 23 Apr 2014 | 3:23 PM ET

CNBC's Becky Quick discusses Warren Buffett's feelings about the market.

Wednesday, 23 Apr 2014 | 12:00 AM ET

Most people probably don't want their six-figure sports cars all marked up, unless it's been marked up by the world's best basketball players. This one-of-a-kind 2002 Aston Martin Vanquish is the only car on the planet to have 50 signatures on it from 50 basketball Hall of Famers, increasing its value over 500 percent.